Traws Pharma, Inc. (TRAW) 股票分析

公司概述

Traws Pharma, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing small-molecule oral product candidates specifically targeting respiratory viral diseases and cancer. The company functions within the healthcare sector, more specifically the biotechnology industry, where it focuses on creating investigational novel therapies for conditions such as influenza and COVID-19. Its current operational scale is defined by a market capitalization of $12.47M, annual revenue of $2.85M over the trailing twelve months, and a workforce of 6 employees. These valuation and revenue figures indicate that Traws Pharma is an early-stage micro-cap entity with limited commercial scale, relying heavily on research and development activities rather than established commercial sales streams.

财务健康

The company reported a revenue of $2.85M for the trailing twelve months, accompanied by a net income loss of $-9,156,000 and an EBITDA of $-15,766,000. The significant negative gap between the modest revenue of $2.85M and the net income loss of $-9,156,000 reveals an extremely high cost structure characterized by substantial operating expenses that far exceed current sales generation. Free cash flow stands at $-11,849,625, indicating that the company is currently burning cash at a rapid pace, which limits its immediate financial flexibility and necessitates continued reliance on external capital sources or existing reserves. Margin analysis shows a gross margin of 100.0%, suggesting no cost of goods sold relative to sales, while the operating margin of -554.6% and profit margin of 0.0% reflect severe operational inefficiencies or high fixed costs typical of pre-revenue biotech firms. The balance sheet holds $6.42M in cash against $0 in debt, presenting a conservative leverage profile despite the lack of traditional equity financing metrics. The current ratio of 1.22 indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a baseline of liquidity for ongoing operations. Return on Equity is -1059.6% and Return on Assets is -92.3%, metrics that reveal that management has not yet generated positive returns on shareholder capital or deployed assets effectively to produce profits.

估值评估

Trailing P/E is listed as N/A due to negative earnings, while the forward P/E is -0.36, implying that the market anticipates continued negative earnings in the near term rather than an immediate profit turnaround. The price-to-book ratio is 2.45, which indicates that the market values the company at a significant premium over its book value, likely reflecting the potential value of its intellectual property and pipeline despite current losses. Alternative valuation metrics include a price-to-sales ratio of 4.38 and an EV/EBITDA of -0.38, suggesting that investors are pricing the stock based on sales potential and asset backing rather than current profitability. The 52-week high is $3.27 and the 52-week low is $0.97, placing the stock's recent trading range within this volatility band where the current price sits at a level that reflects high uncertainty. The beta of 1.62 signifies that the stock's price volatility is substantially higher than the broader market, exposing investors to greater risk swings during periods of market fluctuation.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that historical growth data is unavailable or inconsistent due to the company's recent establishment or lack of prior reporting periods. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests all available resources and potential earnings into research, development, and operational growth rather than distributing income to shareholders. The overall growth and income profile is currently defined by a lack of historical growth data and a complete absence of dividend income, relying entirely on future clinical trial successes and regulatory approvals to drive value appreciation.